| Title: |
Real-World Apremilast Use for Treatment of Plaque Psoriasis in Italy: Patient Perspective, Characteristics, and Clinical Outcomes from the DARWIN Study |
| Authors: |
Giofre, C.; Fabbrocini, G.; Potenza, C.; Tiberio, R.; Gisondi, P.; Marasca, C.; Nuzzo, C. M. A.; Benincasa, E.; Bianchi, L.; Dapavo, P.; Parodi, A.; Atzori, L.; Pasquale, R.; Peris, Ketty; Amerio, P.; Venturini, M.; Schiavo, A. L.; Romanelli, Margherita; Richetta, A.; Cusano, F.; Fargnoli, Maria Concetta; Offidani, A.; Guarneri, C.; Prignano, F.; Corazza, M.; Bongiorno, M. R.; Loconsole, F.; Ori, A.; Simoni, L.; Amici, C.; Palma, L. D.; Andreis, D.; Trevisan, F.; Sala, S.; Patane, R.; Mele, F.; Pernaci, A.; Ruberti, S.; Trogu, M.; Pelicelli, S.; Rizzoli, S.; Peris K. (ORCID:0000-0002-5237-0463); Romanelli M.; Fargnoli M. C. |
| Publisher Information: |
Adis 2023 |
| Document Type: |
Electronic Resource |
| Abstract: |
Introduction: While several European studies have reported real-world apremilast use, patient-perceived benefits, and treatment satisfaction, local reimbursement criteria for apremilast vary and data from Italy are limited. Methods: The cross-sectional DARWIN study enrolled consecutive patients who had initiated apremilast for plaque psoriasis 6 (± 1) months prior to enrolment at a single visit across 24 Italian dermatological sites. Disease severity was assessed using body surface area (BSA) and Physician Global Assessment (PGA). Patient-reported outcomes assessed 6 (± 1) months after apremilast initiation were Dermatology Life Quality Index (DLQI), Patient Benefit Index (PBI), and 9-item Treatment Satisfaction Questionnaire for Medication (TSQM-9). Results: Of 184 patients enrolled between July 2019 and January 2021, 180 were included in the analysis. At apremilast initiation, median (25th–75th percentile) time since psoriasis diagnosis was 8.6 (3.2–22.2) years; median BSA, 10.0% (5.0–16.0); mean (standard seviation, SD) DLQI total score, 13.5 (8.0). Over half (54.9%) of patients with available data reported psoriasis had a very or extremely large effect on their quality of life (QoL); half reported itching (50.6%) and/or special areas involvement (50.0%). Most (73.9%) had comorbidities and were biologic-naïve (81.5%). The most common reasons for initiating apremilast were lack of efficacy of previous treatment (56.7%) and contraindications to other treatments (44.4%). At 6 (± 1) months, most patients were continuing apremilast and/or reported a Global PBI score ≥ 1 (minimum clinical benefit) (86.1% and 90.0%, respectively); approximately half achieved BSA ≤ 3% and/or DLQI total score ≤ 5 (47.1% and 48.5%); 18.8% achieved PGA = 0; mean (SD) TSQM-9 global treatment satisfaction score was 59.0 (24.8). Apremilast was well tolerated; no new safety signals were identified. Conclusions: Patients treated with apremilast for 6 months in Italian clinical practice rep |
| Index Terms: |
Apremilast; Dermatology Life Quality Index; Italian real-world evidence; Patient Benefit Index; Patient perspective; Patient-reported outcomes; Plaque psoriasis; Psoriasis comorbidities; Quality of life; Treatment satisfaction; Settore MED/35 - MALATTIE CUTANEE E VENEREE; info:eu-repo/semantics/article |
| URL: |
https://hdl.handle.net/10807/249100; info:eu-repo/semantics/altIdentifier/pmid/37171752; info:eu-repo/semantics/altIdentifier/wos/WOS:000986364300001; volume:40; issue:7; firstpage:3021; lastpage:3037; numberofpages:17; issueyear:2023; journal:ADVANCES IN THERAPY |
| Availability: |
Open access content. Open access content; info:eu-repo/semantics/openAccess; license:Creative commons; license:Creative commons; license uri:http://creativecommons.org/licenses/by-nc/4.0; license uri:http://creativecommons.org/licenses/by-nc/4.0 |
| Note: |
English |
| Other Numbers: |
SYC oai:publicatt.unicatt.it:10807/249100; 10.1007/s12325-023-02516-y; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85159558924; 1397545809 |
| Contributing Source: |
UNIV CATTOLICA DEL SACRO CUORE; From OAIster®, provided by the OCLC Cooperative. |
| Accession Number: |
edsoai.on1397545809 |
| Database: |
OAIster |